Inovio Pharmaceuticals http://ir.inovio.com/ Inovio Pharmaceuticals DNA Vaccine Against Ebola and Marburg Filoviruses Provides Complete Protection in Preclinical Challenge Study http://ir.inovio.com/2013-05-14-Inovio-Pharmaceuticals-DNA-Vaccine-Against-Ebola-and-Marburg-Filoviruses-Provides-Complete-Protection-in-Preclinical-Challenge-Study Polyvalent Vaccine Design Stimulates Significant Antibody and T-Cell Responses with 100% Survival Against Multiple Families of Most Lethal Virus Known to Man Tue, 14 May 2013 09:16:00 -0400 http://ir.inovio.com/2013-05-14-Inovio-Pharmaceuticals-DNA-Vaccine-Against-Ebola-and-Marburg-Filoviruses-Provides-Complete-Protection-in-Preclinical-Challenge-Study Inovio Pharmaceuticals Reports 2013 First Quarter Financial Results http://ir.inovio.com/2013-05-10-Inovio-Pharmaceuticals-Reports-2013-First-Quarter-Financial-Results Fri, 10 May 2013 16:41:00 -0400 http://ir.inovio.com/2013-05-10-Inovio-Pharmaceuticals-Reports-2013-First-Quarter-Financial-Results Inovio Pharmaceuticals Universal H1N1 Influenza Vaccine Achieves Protective Immune Responses Comparable to Conventional Vaccine in Phase I Study http://ir.inovio.com/2013-04-18-Inovio-Pharmaceuticals-Universal-H1N1-Influenza-Vaccine-Achieves-Protective-Immune-Responses-Comparable-to-Conventional-Vaccine-in-Phase-I-Study Broadly targeted SynCon® H1N1 vaccine induces protective antibodies comparable to current seasonal vaccine against currently circulating influenza strain Thu, 18 Apr 2013 12:00:00 -0400 http://ir.inovio.com/2013-04-18-Inovio-Pharmaceuticals-Universal-H1N1-Influenza-Vaccine-Achieves-Protective-Immune-Responses-Comparable-to-Conventional-Vaccine-in-Phase-I-Study Inovio Pharmaceuticals Recognized With "Best Therapeutic Vaccine" and "Best Early Stage Biotech" Awards at World Vaccine Congress 2013 http://ir.inovio.com/2013-04-18-Inovio-Pharmaceuticals-Recognized-With-Best-Therapeutic-Vaccine-and-Best-Early-Stage-Biotech-Awards-at-World-Vaccine-Congress-2013 Biotech recognized for VGX-3100, an innovative therapy for pre-cancers and cancers caused by HPV, now in phase II for cervical dysplasia Thu, 18 Apr 2013 04:00:00 -0400 http://ir.inovio.com/2013-04-18-Inovio-Pharmaceuticals-Recognized-With-Best-Therapeutic-Vaccine-and-Best-Early-Stage-Biotech-Awards-at-World-Vaccine-Congress-2013 Inovio Pharmaceuticals & U.S. Army Receive $3.5 Million Biodefense Grant to Further Develop Mass Vaccination Device http://ir.inovio.com/2013-04-10-Inovio-Pharmaceuticals-U-S-Army-Receive-3-5-Million-Biodefense-Grant-to-Further-Develop-Mass-Vaccination-Device Inovio to Advance Painless Device to Simultaneously Deliver Multiple Vaccines Using Electroporation Technology Wed, 10 Apr 2013 09:00:00 -0400 http://ir.inovio.com/2013-04-10-Inovio-Pharmaceuticals-U-S-Army-Receive-3-5-Million-Biodefense-Grant-to-Further-Develop-Mass-Vaccination-Device